Stock News

Teekay Offshore Partners LP (TOO) Holder Ci Global Investments Lifted Its Holding by $3.60 Million as Market Valuation Rose; Amicus Therapeutics (FOLD) Stock Rose While Longwood Capital Partners Has Cut by $1.50 Million Its Holding

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Logo

Longwood Capital Partners Llc decreased its stake in Amicus Therapeutics Inc (FOLD) by 70.93% based on its latest 2017Q4 regulatory filing with the SEC. Longwood Capital Partners Llc sold 107,100 shares as the company’s stock rose 0.85% while stock markets declined. The institutional investor held 43,900 shares of the health care company at the end of 2017Q4, valued at $632,000, down from 151,000 at the end of the previous reported quarter. Longwood Capital Partners Llc who had been investing in Amicus Therapeutics Inc for a number of months, seems to be less bullish one the $3.16 billion market cap company. The stock increased 1.09% or $0.18 during the last trading session, reaching $16.74. About 3.00M shares traded or 11.01% up from the average. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 90.40% since May 19, 2017 and is uptrending. It has outperformed by 78.85% the S&P500.

Ci Global Investments Inc increased its stake in Teekay Offshore Partners LP (TOO) by 72% based on its latest 2017Q4 regulatory filing with the SEC. Ci Global Investments Inc bought 1.80 million shares as the company’s stock rose 1.75% while stock markets declined. The institutional investor held 4.30M shares of the marine transportation company at the end of 2017Q4, valued at $10.15 million, up from 2.50 million at the end of the previous reported quarter. Ci Global Investments Inc who had been investing in Teekay Offshore Partners LP for a number of months, seems to be bullish on the $1.15 billion market cap company. The stock decreased 6.21% or $0.18 during the last trading session, reaching $2.72. About 649,264 shares traded or 50.98% up from the average. Teekay Offshore Partners L.P. (NYSE:TOO) has declined 51.56% since May 19, 2017 and is downtrending. It has underperformed by 63.11% the S&P500.

More notable recent Teekay Offshore Partners L.P. (NYSE:TOO) news were published by: Benzinga.com which released: “Earnings Scheduled For May 17, 2018” on May 17, 2018, also Globenewswire.com with their article: “Teekay Offshore Partners Reports First Quarter 2018 Results” published on May 17, 2018, Globenewswire.com published: “Teekay Offshore Partners Announces Management Change” on May 03, 2018. More interesting news about Teekay Offshore Partners L.P. (NYSE:TOO) were released by: Globenewswire.com and their article: “Teekay Group Announces First Quarter 2018 Earnings Results Conference Calls” published on May 08, 2018 as well as Seekingalpha.com‘s news article titled: “Teekay Offshore Partners’ (TOO) CEO Ingvild Sæther on Q1 2018 Results – Earnings Call Transcript” with publication date: May 17, 2018.

Ci Global Investments Inc, which manages about $9.58B and $5.19 billion US Long portfolio, decreased its stake in Enterprise Prods Partners L (NYSE:EPD) by 121,506 shares to 56,851 shares, valued at $1.51 million in 2017Q4, according to the filing. It also reduced its holding in Unitedhealth Group Inc (NYSE:UNH) by 36,498 shares in the quarter, leaving it with 47,122 shares, and cut its stake in Franco Nevada Corp (NYSE:FNV).

Among 9 analysts covering Teekay Offshore (NYSE:TOO), 5 have Buy rating, 1 Sell and 3 Hold. Therefore 56% are positive. Teekay Offshore had 17 analyst reports since August 4, 2015 according to SRatingsIntel. Morgan Stanley upgraded the shares of TOO in report on Monday, February 12 to “Equal-Weight” rating. The rating was downgraded by Raymond James on Friday, July 28 to “Market Perform”. The firm has “Sector Perform” rating given on Thursday, December 17 by RBC Capital Markets. The company was maintained on Monday, June 20 by UBS. As per Tuesday, August 4, the company rating was upgraded by Global Hunter Securities. The rating was maintained by UBS on Wednesday, November 15 with “Buy”. The firm earned “Underperform” rating on Thursday, December 17 by Bank of America. The company was upgraded on Thursday, August 18 by RBC Capital Markets. The stock of Teekay Offshore Partners L.P. (NYSE:TOO) earned “Buy” rating by Citigroup on Wednesday, July 26. The rating was upgraded by Wells Fargo on Thursday, September 14 to “Outperform”.

Investors sentiment decreased to 0.79 in Q4 2017. Its down 0.11, from 0.9 in 2017Q3. It dived, as 14 investors sold TOO shares while 20 reduced holdings. 15 funds opened positions while 12 raised stakes. 73.81 million shares or 3.75% more from 71.14 million shares in 2017Q3 were reported. 4.41 million are owned by Eagle Global Advsrs Limited Liability Corp. Magnetar Financial Ltd holds 0.73% of its portfolio in Teekay Offshore Partners L.P. (NYSE:TOO) for 12.54 million shares. Stratos Wealth Prtnrs Limited has invested 0% in Teekay Offshore Partners L.P. (NYSE:TOO). Key Gru (Cayman) has invested 0.19% in Teekay Offshore Partners L.P. (NYSE:TOO). Luminus Mgmt Limited Liability Com has invested 0.55% in Teekay Offshore Partners L.P. (NYSE:TOO). Pinnacle Holdg Limited Liability invested in 0.01% or 9,457 shares. Invesco holds 0% or 386,971 shares in its portfolio. Integral Derivatives Ltd Llc invested 0% in Teekay Offshore Partners L.P. (NYSE:TOO). Natixis owns 0% invested in Teekay Offshore Partners L.P. (NYSE:TOO) for 25,000 shares. Exane Derivatives accumulated 0% or 53 shares. Royal National Bank & Trust Of Canada has invested 0% of its portfolio in Teekay Offshore Partners L.P. (NYSE:TOO). Guggenheim Capital Llc invested 0.01% of its portfolio in Teekay Offshore Partners L.P. (NYSE:TOO). Citadel Limited Company invested 0% of its portfolio in Teekay Offshore Partners L.P. (NYSE:TOO). Jpmorgan Chase And Communication reported 61,000 shares or 0% of all its holdings. Northern Trust stated it has 0% of its portfolio in Teekay Offshore Partners L.P. (NYSE:TOO).

Since December 11, 2017, it had 3 insider purchases, and 19 sales for $3.49 million activity. The insider Barth Jay sold $336,000. On Tuesday, January 2 Baird William D III sold $147,181 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 10,000 shares. 100,000 shares were bought by PERCEPTIVE ADVISORS LLC, worth $1.39 million on Friday, March 2. Andrews Kurt J. also sold $147,191 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares. RAAB MICHAEL sold $140,490 worth of stock. 8,750 shares were sold by Quimi Daphne, worth $131,250.

Investors sentiment decreased to 1.21 in 2017 Q4. Its down 1.12, from 2.33 in 2017Q3. It worsened, as 25 investors sold FOLD shares while 48 reduced holdings. 25 funds opened positions while 63 raised stakes. 197.59 million shares or 2.54% more from 192.70 million shares in 2017Q3 were reported. 17.89M were reported by Perceptive Advsr Lc. Gradient Invests Ltd Liability Company holds 4,000 shares. Numeric Ltd Liability Co holds 192,431 shares or 0.02% of its portfolio. Goldman Sachs reported 1.56 million shares. Citadel Advsr Ltd Liability holds 3.67 million shares or 0.03% of its portfolio. Highland Cap Management Limited Partnership holds 0.19% or 292,000 shares. Principal Grp holds 0% or 125,621 shares. California State Teachers Retirement Systems invested in 263,224 shares or 0.01% of the stock. Ardsley Advisory stated it has 0.58% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Sectoral Asset Management Inc has invested 5.13% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). State Of Wisconsin Investment Board reported 0.01% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Lpl Ltd Co invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Artal Grp Incorporated stated it has 0.22% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). The New York-based J Goldman & Com Lp has invested 0.17% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Swiss Financial Bank stated it has 252,200 shares or 0% of all its holdings.

Among 9 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Amicus Therapeutics had 22 analyst reports since August 18, 2015 according to SRatingsIntel. The company was maintained on Tuesday, September 1 by Cowen & Co. The firm has “Buy” rating by Zacks given on Tuesday, August 18. The rating was upgraded by Robert W. Baird on Tuesday, January 24 to “Outperform”. The stock has “Buy” rating by Robert W. Baird on Wednesday, February 7. Goldman Sachs initiated the stock with “Neutral” rating in Wednesday, March 30 report. The firm has “Buy” rating by Cowen & Co given on Monday, August 7. Chardan Capital Markets upgraded it to “Buy” rating and $8 target in Monday, October 5 report. The stock has “Outperform” rating by Leerink Swann on Monday, October 5. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has “Buy” rating given on Sunday, August 13 by Cowen & Co. As per Wednesday, May 18, the company rating was initiated by Bank of America.

Analysts await Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report earnings on August, 6. They expect $-0.33 earnings per share, up 2.94% or $0.01 from last year’s $-0.34 per share. After $-0.28 actual earnings per share reported by Amicus Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 17.86% negative EPS growth.

Longwood Capital Partners Llc, which manages about $529.67M US Long portfolio, upped its stake in Amag Pharmaceuticals Inc (Put) (NASDAQ:AMAG) by 82,500 shares to 132,500 shares, valued at $1.76 million in 2017Q4, according to the filing. It also increased its holding in Kadmon Hldgs Inc by 1.58M shares in the quarter, for a total of 4.92 million shares, and has risen its stake in Assembly Biosciences Inc (NASDAQ:ASMB).

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *